Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?

Hemopathy Clinical Trial

— REPLIPO  

Official title:

Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03102905
• Other study ID #: PI2016_843_0017
• Status: Recruiting
• Phase: N/A
• First received: March 31, 2017
• Last updated: March 31, 2017
• Start date: December 13, 2016
• Est. completion date: June 13, 2017

Study information

• Verified date: March 2017
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Guillaume CHABY, Dr
• Phone: +33322455846
• Email: chaby.guillaume[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To look for the replication of HHV6 by PCR in the skin, in these patients with haemopathies presenting an exanthema. This will make it possible to evaluate the prevalence of the positivity of this PCR in the skin. Then the investigator can investigate whether there is an association between the positivity of HHV6 PCR in the blood and / or skin and the viral etiology of the exanthema. If this association exists, it will make it possible to improve the diagnosis in the context of the exanthema and thus to improve the therapeutic management of these patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: June 13, 2017
• Est. primary completion date: June 13, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Supported for any type of hemopathy.

• Allograft, autografted or ungrafted haematopoietic stem cells

• Having presented an exanthema during hospitalization, for which a cutaneous biopsy had been performed

• Having had a blood test of the HHV6 virus by PCR at least within the previous 40 days or following the rash.

• Age greater than or equal to 18 years

• Patient informed of the protocol by post, not having refused within one month of sending the said courier.

Exclusion Criteria:

• Patient who refused the search.

• Patient whose HHV6 PCR in the blood was carried out at a distance of more than 40 days from the skin biopsy.

Related Conditions & MeSH terms

• Exanthema
• Hemopathy
• HHV6

Intervention

Other:
• Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.
To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.

Locations

Country	Name	City	State
France	CHU Amiens Picardie	Amiens	Picardie

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.		1 day